A unique shareholding structure

Pierre Fabre Laboratories is characterized by a unique shareholding structure: its only shareholders are the Foundation of the same name, and the company’s employees, with the Foundation holding the majority share (86%).

This specific structure guarantees the company’s independence, and fosters a long-term vision that benefits patients, consumers, employees and all of our stakeholders. 

All dividends are channeled into the humanitarian projects run by the Fondation Pierre Fabre.

The Foundation is the majority shareholder

Fondation Pierre Fabre works tirelessly to improve access to drugs and quality healthcare in the Global South. It focuses on 5 priority areas to improve health: the training of drugs specialists, healthcare access for vulnerable populations, combating sickle-cell disease, dermatology in tropical regions, and e-health. It manages over 30 programs in Sub-Saharan Africa, South-East Asia, Haiti and Lebanon.

To find out more about the programs run by the Foundation.

Employees, the co-owners of the company

Employees, as the second group of shareholders, own 9.5% of the share capital via the Ruscus employee stock ownership scheme. This scheme, launched in France in 2005 and extended to thirteen other countries, offers employees the chance to participate in the company’s growth and share in its success. In 2022, 86% of eligible employees had become shareholders, proof of their confidence in the strategy and success of Pierre Fabre Laboratories. This distinctive model fosters a fair distribution of the value created by each person’s hard work, and confirms employees’ commitment to preserving it.